ES2522317T3 - Ticagrelor para tratamiento de aneurismas aórticos abdominales - Google Patents

Ticagrelor para tratamiento de aneurismas aórticos abdominales Download PDF

Info

Publication number
ES2522317T3
ES2522317T3 ES08857354.8T ES08857354T ES2522317T3 ES 2522317 T3 ES2522317 T3 ES 2522317T3 ES 08857354 T ES08857354 T ES 08857354T ES 2522317 T3 ES2522317 T3 ES 2522317T3
Authority
ES
Spain
Prior art keywords
treatment
ticagrelor
aortic aneurysms
abdominal aortic
aneurysms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08857354.8T
Other languages
English (en)
Inventor
Jean-Baptiste Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2522317T3 publication Critical patent/ES2522317T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso del compuesto {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)- 3H-1,2,3- triazolo[4,5-d] pirimidin-3-il)-5-(2-hidroxietoxi)ciclopentano-1,2-diol para la fabricación de un medicamento para el tratamiento de aneurismas aórticos abdominales.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08857354.8T 2007-12-03 2008-12-02 Ticagrelor para tratamiento de aneurismas aórticos abdominales Active ES2522317T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301616 2007-12-03
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (1)

Publication Number Publication Date
ES2522317T3 true ES2522317T3 (es) 2014-11-14

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08857354.8T Active ES2522317T3 (es) 2007-12-03 2008-12-02 Ticagrelor para tratamiento de aneurismas aórticos abdominales

Country Status (24)

Country Link
US (2) US20100298350A1 (es)
EP (1) EP2229172B1 (es)
JP (1) JP5701060B2 (es)
KR (1) KR101563757B1 (es)
CN (2) CN101883565A (es)
AU (1) AU2008331984B2 (es)
BR (1) BRPI0819458A2 (es)
CA (1) CA2707488C (es)
CY (1) CY1115760T1 (es)
DK (1) DK2229172T3 (es)
EA (1) EA201000928A1 (es)
ES (1) ES2522317T3 (es)
HR (1) HRP20141081T1 (es)
IL (1) IL205613A (es)
MX (1) MX2010006101A (es)
MY (1) MY159656A (es)
NZ (1) NZ585513A (es)
PL (1) PL2229172T3 (es)
PT (1) PT2229172E (es)
RS (1) RS53635B1 (es)
SI (1) SI2229172T1 (es)
UA (1) UA100864C2 (es)
WO (1) WO2009072967A1 (es)
ZA (1) ZA201003599B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
US9539246B2 (en) 2011-08-30 2017-01-10 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221880B1 (hu) * 1995-07-11 2003-02-28 Astrazeneca Ab, Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Also Published As

Publication number Publication date
DK2229172T3 (da) 2014-11-10
AU2008331984B2 (en) 2012-08-16
HK1148195A1 (en) 2011-09-02
PT2229172E (pt) 2014-11-03
CY1115760T1 (el) 2017-01-25
MX2010006101A (es) 2010-10-04
AU2008331984A1 (en) 2009-06-11
ZA201003599B (en) 2012-10-31
KR101563757B1 (ko) 2015-10-27
CA2707488C (en) 2015-07-28
CN103919781A (zh) 2014-07-16
PL2229172T3 (pl) 2015-01-30
KR20100099175A (ko) 2010-09-10
IL205613A0 (en) 2010-11-30
US20100298350A1 (en) 2010-11-25
CA2707488A1 (en) 2009-06-11
MY159656A (en) 2017-01-13
RS53635B1 (sr) 2015-04-30
IL205613A (en) 2015-04-30
UA100864C2 (uk) 2013-02-11
BRPI0819458A2 (pt) 2015-05-05
NZ585513A (en) 2012-07-27
JP2011505417A (ja) 2011-02-24
JP5701060B2 (ja) 2015-04-15
EP2229172A1 (en) 2010-09-22
HRP20141081T1 (hr) 2015-01-02
CN101883565A (zh) 2010-11-10
SI2229172T1 (sl) 2014-12-31
EP2229172B1 (en) 2014-09-10
EA201000928A1 (ru) 2010-12-30
EP2229172A4 (en) 2012-12-26
US20150272955A1 (en) 2015-10-01
WO2009072967A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
CL2011002955A1 (es) Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades.
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
MY147966A (en) Compositions, suitable for oral administration, comprising a triazolo [4,5-d] pyrimidin derivate
CL2008003023A1 (es) (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer.
AR054426A1 (es) Uso de un inhibidor de la dimerizacion de receptores tirosina quinasas her para la manufactura de un medicamento para alargar el tiempo hasta l a progresion de la enfermedad o la supervivencia de los pacientes de cancer
ES2562651T3 (es) Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
UY30094A1 (es) Compuestos químicos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
ES2555778T3 (es) Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
NI201400052A (es) Composiciones farmacéuticas de 7 - ( 6 - ( 2 - hidroxipropano - 2 - il ) piridina - 3 - il ) - 1 - ((trans) - 4 - metoxiciclohexil ) - 3, 4 - dihidropirazino [ 2, 3 - b ] pirazina - 2 ( 1h ) - ona, una forma sólida de las mismas y métodos de su uso
ECSP10010695A (es) Compuestos de piridina
ECSP099044A (es) Compuestos de pirimido fusionados
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CL2014001309A1 (es) Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.
ECSP14013130A (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
CL2008003396A1 (es) (3ar,4s,6r,6as)-6-amino-2,2-dimetiltetrahidro-3ah-ciclopena[d][1,3]dioxol-4-ol dibenzoil-l-tartrato y su proceso de preparación.
CR11591A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
MX393334B (es) Administración subcutánea de un antagonista del receptor p2y12.
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp